BioSpace News Archive

POXEL SA announced changes in its management team, with the appointment of Quentin Durand as Chief Legal Officer, and the departure of Christophe Arbet-Engels, MD, PhD, MBA, Chief Medical Officer and Executive Vice President Late Development & Medical Affairs.

Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced that Stemline management will present at Piper Jaffray’s 31st Annual Healthcare Conference on Tuesday, December 3rd at 1:30 PM EST at the Lotte New York Palace Hotel in New York City.

Hemostemix Inc. announces the appointment of Mr. Thomas Smeenk, BA, to the Company’s board of directors effective November 26, 2019, subject to customary TSX Venture Exchange approval.

PTC Therapeutics, Inc. announced that on November 25, 2019 it approved non-statutory stock options to purchase an aggregate of 144,550 shares of its common stock to 36 new employees.

Medexus Pharmaceuticals Inc. provided a business update and announced its financial and operating results for the three- and six-month periods ended September 30, 2019.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2019, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to fourteen individuals hired by Sarepta in November 2019.

Alligator Bioscience announced that the company has appointed Dr Malin Carlsson as Chief Operating Officer.

Demand for the international medical imaging IT and cybersecurity company Sectra’s products increased and record-high order bookings were reported for the most recent 12-month period.

Ra Medical Systems, Inc., a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three and nine months ended September 30, 2019.

Sonoma Pharmaceuticals, Inc. announced the closing of a public offering of 446,577 shares of common stock at a public offering price of $3.50 per share..